Inclusion criteria | |
---|---|
Consent | Willing and able to give informed consent for participation in the trial, reconfirmed verbally at each clinic visit |
Agree to have study visits video and/or audio recorded | |
Agree to inform the Investigators within 48 h of any medical conditions and procedures being undertaken | |
Willing for the investigators to communicate directly with their medical team to determine medical suitability for study participation (oncologist, GP, palliative care physician, etc.) | |
Agree to refrain from starting any new psychiatric medication and/or psychotherapy during the study period | |
Agree to have transportation other than driving themselves to where they are staying on the days of medication dosing | |
Able and willing to be contacted via telephone for all necessary telephone contacts | |
Agree to use an effective form of contraception if of child-bearing potential for the duration of medication dosing | |
Must provide a contact/support person if they are unreachable by study staff or in the event of severe distress or suicidality | |
Agree to not use any medications on the prohibited medications list during the study | |
Agree not to take any herbal supplement for the duration of medication dosing (except with prior approval of the research team) | |
Demographics | At least 25 years old |
Proficient in speaking and reading English | |
Clinical characteristics | Diagnosis with an incurable stage IV incurable solid organ malignancy |
Prognosis of at least 6 months life expectancy from the time of screening | |
Moderate distress (4 or greater) as measured by the distress thermometer |